Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil

Oncology Reports

Volumn 9, Issue 4, 2002, Pages 783-787

  Shimada, Shinya ^a,b   Yagi, Yasushi ^c   Shiomori, Kenji ^a   Kuramoto, Masafumi ^b   Aoki, Norimitsu ^b   Ogawa, Michio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Yatsushiro Social Insurance General Hospital   (Japan)

^c Kumamoto Regional Medical Center   (Japan)

Author keywords

5 fluorouracil; Chemotherapy; Cisplatin; Colorectal cancer; Irinotecan; Metastasis; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADENOCARCINOMA; ADULT; AGED; AMBULATORY CARE; ARTICLE; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DIARRHEA; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; MIDDLE AGED; NAUSEA; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA;

EID: 0036634923     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.4.783     Document Type: Article

References (27)

1. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-755, 1993. (Pubitemid 23080053)
2. Grem JL: Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 24 (Suppl 18): S18-8-S18-18, 1997.
3. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G and Piedbois P: Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356: 373-378, 2000. (Pubitemid 30487493)
4. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-l, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145, 2000. (Pubitemid 30411708)
5. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7: 1419-1426, 1989. (Pubitemid 19245111)
6. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
7. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG and Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20, 1994.
8. Jager E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Buschenfelde KH and Knuth A: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14: 2274-2279, 1996. (Pubitemid 26264878)
9. Porschen R, Bermann A, Loftier T, Haack G, Rettig K, Anger Y and Strohmeyer G: Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 19: 1787-1794, 2001. (Pubitemid 32230881)
10. Falcone A, Allegrini G, Masi G, Lencioni M, Pfanner E, Brunetti I, Danesi R, Bocci G, Del Tacca M and Conte P: 5-Fluorouracil administered as a 48-h chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 61: 28-35, 2001. (Pubitemid 32734083)
11. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO and Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292,2001. (Pubitemid 32366981)
12. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987. (Pubitemid 18018734)
13. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569, 1987.
14. Hsiang YH, Liu LF, Wall ME, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 15: 4385-4389, 1989. (Pubitemid 19208330)
15. Kigawa J, Takahashi M, Minagawa Y, et al: Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer 84: 521-524, 1999.
16. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11: 909-913, 1993. (Pubitemid 23146086)
17. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999. (Pubitemid 29022409)
18. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15: 921-927, 1997. (Pubitemid 27106273)
19. Kanzawa F, Koizumi F, Koh Y, et al: In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7: 202-209, 2001. (Pubitemid 32110224)
20. Tsunoda T, Tanimura H, Hotta T, et al: In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. J Surg Oncol 73: 6-11, 2000. (Pubitemid 30067526)
21. Fukuda M, Nishio K, Kanzawa F, et al: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56: 789-793, 1996.
22. Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W and Depisch D: Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a phase I-II trial. Cancer 91: 1264-1271, 2001. (Pubitemid 32267036)
23. World Health Organization: WHO handbook for reporting results for gastric cancer treatment. World Health Organization, Geneva, 1979.
24. Berlin J: Second-line therapy in colorectal cancer. Oncology 14 (Suppl 11): 21-26,2000.
25. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
26. Takahashi Y, Mai M, Taguchi T, Umshizaki I and Nishioka K: Prolonged stable disease affects survival in patients with solid gastric tumors: analysis of phase II studies of doxifluridine. Int J Oncol 17: 285-289, 2000.
27. Bonetti A, Zaninelli M, Leone R, Franceschi T, Fraccon AP, Pasini F, Sabbioni R, Cetto GL, Sich D, Brienza S and Howell SB: Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann Oncol 12: 187-191, 2001. (Pubitemid 32223866)